

Fluticasone furoate, umeclidinium bromide and vilanterol (Trelegy[®] Ellipta[®]) for chronic obstructive pulmonary disease (COPD)

NHS Devon

Commissioning policy

The routine commissioning of Trelegy[®] Ellipta[®] is accepted in Devon for maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD). The Formulary Interface Group should include this in locally defined treatment recommendations.

Rationale for the decision

Trelegy[®] Ellipta[®] is a triple therapy dry-powder inhaler (DPI) containing fluticasone furoate, umeclidinium bromide and vilanterol (as trifenate) and is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting β 2-agonist.

It has been shown that Trelegy[®] Ellipta[®] improves symptoms, lung function and quality of life as well as significantly lowering the rate of moderate or severe COPD exacerbations when compared to dual therapy.

Trelegy[®] Ellipta[®] offers patients a single triple-therapy DPI device as an alternative for those patients that are unable to use a metered dose inhaler, and is considered to offer good value for money.

Guidance notes on exceptionality

Not applicable.

Date of publication:	Version:
15.11.2018	Policy agreed by Northern, Eastern and Western Devon CCG and South Devon and Torbay CCG Policy adopted by NHS Devon CCG on 01.04.2019 Policy adopted by NHS Devon ICB on 01.07.2022